AMNEAL PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
AMNEAL PHARMACEUTICALS, INC. (AMRX) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $50.30 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2024-11-12
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $50.30M.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $79.67M.
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $119.43M.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $40.61M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2024-09-30 | $50.30M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $79.67M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $119.43M 10-Q · filed 2024-05-08 |
| 2023-09-30 | $40.61M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $81.13M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $121.94M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $45.50M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $88.56M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $126.85M 10-Q · filed 2022-05-06 |
| 2021-09-30 | $43.70M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $87.05M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $125.09M 10-Q · filed 2021-05-07 |
| 2020-09-30 | $43.80M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $88.63M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $137.06M 10-Q · filed 2020-05-11 |
| 2019-09-30 | $40.16M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $76.02M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $90.20M 10-Q · filed 2019-05-09 |
| 2018-09-30 | $25.96M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $52.83M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |